海洋性生体材料フコイダンナノスカベンジャーの構築とその大腸炎治療への応用
Chunjing Guo1, Yuxin Cao2, Yiyang Sun3
1Department of Food and Biochemical Engineering, Yantai Vocational College, Yantai, 264670, China.
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that primarily affects the colon and rectum and is characterized by diffuse, superficial inflammation of the colonic mucosa. The excessive production of reactive oxygen species (ROS) plays a pivotal role in immune dysregulation and the pathogenesis of UC. However, current treatment options are limited by poor absorption, rapid metabolism, and systemic side effects due to the lack of targeted delivery. Therefore, there is an urgent need for therapies capable of specifically scavenging ROS. In this study, we developed a ROS-responsive nanoscavenger system, Fucoidan-TK-Resveratrol@Curcumin (FTR@Cur), based on the marine-derived polysaccharide fucoidan, and loaded with the natural compound curcumin (Cur) for the treatment of UC. The nanoscavenger was constructed using fucoidan (Fuc) as the hydrophilic backbone, while resveratrol (Res) was conjugated via a ROS-sensitive thioketal (TK) linker, enabling targeted ROS clearance. The resulting FTR@Cur nanoparticles had a mean particle size of 92.17 nm, a zeta potential of -22.2 mV, and an encapsulation efficiency and drug loading of 69.0% and 5.5%. FTR@Cur exhibited excellent ROS-scavenging ability and biocompatibility, effectively modulating the inflammatory and immune microenvironment in the colon. This system enhanced colonic barrier function, reduced inflammation, and offers a promising therapeutic strategy for UC.
さらに関連する動画
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
